Thiazolidinediones: an update

Lancet. 2000 Mar 18;355(9208):1008-10. doi: 10.1016/S0140-6736(00)90002-3.


Thiazolidinediones, which are being developed for the treatment of insulin resistance and type 2 diabetes mellitus, bind and activate peroxisome proliferator-activated receptor gamma, a nuclear receptor that regulates the expression of several genes involved in metabolism. This receptor controls adipocyte differentation, lipid storage, and insulin sensitisation. Besides metabolic activities, thiazolidinediones have effects as diverse as the control of host defence, cell proliferation, and tumorigenesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipose Tissue / drug effects
  • DNA-Binding Proteins / pharmacology
  • Diabetes Mellitus / drug therapy
  • Humans
  • Insulin Resistance
  • Molecular Conformation
  • Receptors, Cytoplasmic and Nuclear / analysis
  • Signal Transduction / drug effects
  • Thiazoles / pharmacology*
  • Thiazoles / therapeutic use
  • Thiazolidinediones*
  • Transcription Factors / analysis


  • DNA-Binding Proteins
  • Receptors, Cytoplasmic and Nuclear
  • Thiazoles
  • Thiazolidinediones
  • Transcription Factors
  • 2,4-thiazolidinedione